{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "AVNS", "name": "Avanos Medical, Inc.", "url": "https://frontierpicks.com/dossiers/AVNS/", "json_url": "https://frontierpicks.com/dossiers/AVNS.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Resolved, not pending: AIP completed the $25.00/share all-cash take-private on 2026-07-27 and AVNS ceased NYSE trading the same day (EV ~$1.272B). Holders received cash; there is no listed security, no narrative leg and no catalyst left. The file is a closed record — dead as of 2026-07-27.", "invalidation_trigger": "A daily close below $25.00 is no longer printable: AVNS regular-way trading ended with the 2026-07-27 completion of the $25.00/share AIP merger and NYSE delisting, so no tape exists to break. Only a resumed listing — an unwound deal or a reassigned symbol — would reopen the name.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "m-and-a-special-situations", "medtech-diagnostics" ], "tags": [], "sources": [], "notes": [ "Merger completed 2026-07-27: AVNS common stock ceased trading on the NYSE the same day and Avanos is now a private AIP portfolio company.", "No US-listed AVNS equity exists after 2026-07-27 — any quote still displayed by a data vendor is a stale final print, not a live market.", "Cash consideration was $25.00/share; the last completed daily close in the adjusted series was $24.99 on 2026-07-24, 52-week high $25.05.", "Public reporting ends with deregistration — the Form 10-Q for the quarter ended 2026-03-31 (CIK 0001606498) is the last quarterly filing on EDGAR.", "Ticker symbols are recycled: any future AVNS price series would belong to a different issuer and should not be spliced onto this history." ], "body_markdown": "## Current Thesis\nResolved, not pending. American Industrial Partners completed the acquisition of Avanos Medical on **2026-07-27** at **$25.00 per share in cash**, an enterprise value of approximately **$1.272 billion**, and the common stock ceased trading on the NYSE the same day (AIP press release, 2026-07-27). The guided completion date in the prior note — no later than 2026-07-27 — arrived on schedule and the equity was extinguished into cash. The narrative is **dead**, dated 2026-07-27. That is the only one of the four site labels that fits: the listing structure is gone. The nuance a reader should carry is that it ended by completion at par, not by a failed narrative — the payoff was delivered exactly as contracted, and then the instrument stopped existing. Everything below is a closed record and a set of read-across facts, because there is no US-listed share to analyse.\n\n## Bull Case\n- the two failure modes that kill most sponsor deals never engaged.\n- The path was dated and clean: all required regulatory clearances received **2026-07-02**; stockholder approval **2026-07-22** with roughly **99.75% of votes cast** in favour, representing about **74.96% of shares outstanding** as of the 2026-06-18 record date; completion **2026-07-27**.\n- Operating results never became the pressure point: Q1 reported **2026-05-05** showed adjusted EPS **$0.22 vs $0.14** consensus and sales **$182.2M vs $170.0M** consensus.\n- The whole distribution was one gap. From the 2026-04-13 close of roughly **$14.53** to the $25.00 consideration — a **72.1% premium** — the re-rating printed in the 2026-04-14 session (shares +69%). The three months that followed paid only the residual settlement spread.\n\n## Bear Case\n- **There is nothing to trade.** Regular-way NYSE trading in AVNS was suspended on 2026-07-27; the company requested delisting via Form 25 and is now a wholly owned subsidiary of A-AV Holdco I, Inc.\n- Any AVNS quote still visible on a screen is a stale final print. The last reference close in the split/dividend-adjusted daily series was **$24.99 on 2026-07-24**, against a 52-week high of **$25.05** — those numbers no longer update.\n- Public disclosure ends. The Form 10-Q for the quarter ended **2026-03-31** (CIK 0001606498) is the last quarterly report on EDGAR; deregistration removes the reporting obligation, so there is no future print against which any fundamental view could be graded. (Inference, from the going-private structure — not a filed statement.)\n- Symbol reuse is a live contamination risk for anything mechanical. Exchanges recycle tickers; a future AVNS price series would belong to a different issuer, and a screen keying on ticker rather than listing status would silently splice two unrelated companies.\n\n## Setup & Price Structure\nThe last completed daily close was **$24.99 on 2026-07-24**, 0.2% below the 52-week high of **$25.05** — roughly a four-basis-point discount to the $25.00 consideration, which is settlement mechanics rather than a market opinion. Three-month return into that date: **1.3%**. RSI(14) printed **76.9**, an artifact of the 2026-04-14 gap from ~$14.53 rather than evidence of demand; the same distortion produced Benzinga's 2026-05-04 \"may collapse this month\" screen at RSI 90. Moving averages, breakout shelves and oscillators carried no information on a contractually pinned price and now have no series behind them at all. On positioning, the observable worth recording is index-mechanical: S&P Dow Jones Indices announced on **2026-07-20** that V2X would replace AVNS in the S&P SmallCap 600 before the open on **2026-07-27**, which forced passive deletion into the same session that trading stopped. The residual holder base into the close was merger arbitrage collecting a spread measured in days.\n\n## Catalyst Calendar (next 30 days)\n\n- **None.** No earnings date, no shareholder meeting, no regulatory decision and no scheduled corporate event exists for a private company. The Q2 report that would have landed in early August 2026 was never filed as a public company.\n- Post-close administrative filings (Form 25 / Form 15 deregistration) are housekeeping and carry no economic content.\n\n## Elapsed catalysts\n\n- **2026-07-27 (elapsed)** — merger completion, NYSE trading suspension, Form 25 delisting request. This was the terminal dated event in the name. *(passed 30d ago)*\n\n## What Would Change Our Mind\nThe structure that would have to reappear is a listing. Nothing about Avanos's business, guidance or multiple can move this read, because no security references it: the only development that reopens analysis is regular-way AVNS trading resuming on a US exchange, which would imply either an unwound merger — for which there is no evidence — or the reassignment of the symbol to an unrelated issuer. Stated in gradeable form: **a daily close below $25.00** in a legitimate AVNS series would indicate something other than a completed $25.00 all-cash merger, and no such print can exist while the company is held privately by AIP. A secondary condition that would demand a fresh look is a Delaware appraisal petition by dissenting holders that puts a per-share number other than $25.00 into the record. Absent one of those two observables, the name stays retired and this file is a historical entry.\n\n## Correlation Notes\n- Live correlation is undefined after 2026-07-27. There is no return series, so beta to XLV, IHI or any small-cap benchmark cannot be computed forward.\n- Pre-close the name had already decoupled from healthcare: from the 2026-04-14 announcement to the 2026-07-24 final close the stock moved 1.3% over three months while sector indices traded on their own drivers — a cash-clamped price tracks the calendar and the discount rate, not the group.\n- The read-across that survives is the comp. AIP paid **$1.272B EV** and a **72.1% premium** to the undisturbed 2026-04-13 close for a medtech running roughly **$182M** of quarterly sales with improving margins. That pairing of premium and multiple is the reference point for the next sponsor approach in small-cap medtech, and it is the reason RSI-driven \"overbought\" screens on any small-cap with an unexplained 60%+ single-session gap deserve a check of the deal tape before they are read as momentum.", "first_seen": "2026-04-19", "last_analyzed": "2026-08-16T14:14:21+00:00", "last_synthesized": "2026-08-16", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }